Trial Profile
A Multi-center, Randomized, Double Blinded, Parallel-group Study to Assess the Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs NBP 608 (Primary) ; Varicella zoster virus vaccine live
- Indications Herpes zoster; Varicella zoster virus infections
- Focus Pharmacodynamics
- Sponsors SK Chemicals
- 19 Apr 2017 New trial record